Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Depreciation Expense (2016 - 2020)

Ani Pharmaceuticals' Depreciation Expense history spans 9 years, with the latest figure at $1.3 million for Q4 2020.

  • For Q4 2020, Depreciation Expense rose 8.33% year-over-year to $1.3 million; the TTM value through Dec 2020 reached $4.8 million, up 6.67%, while the annual FY2025 figure was $8.9 million, 20.27% up from the prior year.
  • Depreciation Expense for Q4 2020 was $1.3 million at Ani Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Depreciation Expense topped out at $1.3 million in Q4 2020 and bottomed at $200000.0 in Q1 2016.
  • The 5-year median for Depreciation Expense is $500000.0 (2018), against an average of $670000.0.
  • The largest annual shift saw Depreciation Expense changed 0.0% in 2016 before it surged 300.0% in 2019.
  • A 5-year view of Depreciation Expense shows it stood at $200000.0 in 2016, then soared by 50.0% to $300000.0 in 2017, then skyrocketed by 166.67% to $800000.0 in 2018, then soared by 50.0% to $1.2 million in 2019, then increased by 8.33% to $1.3 million in 2020.
  • Per Business Quant, the three most recent readings for ANIP's Depreciation Expense are $1.3 million (Q4 2020), $1.1 million (Q3 2020), and $1.2 million (Q2 2020).